Page 61 - Read Online

Liu et al. Hepatoma Res 2020;6:7 I http://dx.doi.org/10.20517/2394-5079.2019.39 Page 15 of 16

to study human cancer. Nat Genet 2004;36:1306-11.
41. Inokuchi S, Aoyama T, Miura K, Osterreicher CH, Kodama Y, et al. Disruption of TAK1 in hepatocytes causes hepatic injury,
inflammation, fibrosis, and carcinogenesis. Proc Natl Acad Sci U S A 2010;107:844-9.
42. Katzenellenbogen M, Mizrahi L, Pappo O, Klopstock N, Olam D, et al. Molecular mechanisms of liver carcinogenesis in the mdr2-
knockout mice. Mol Cancer Res 2007;5:1159-70.
43. Popov Y, Patsenker E, Fickert P, Trauner M, Schuppan D. Mdr2 (Abcb4)-/- mice spontaneously develop severe biliary fibrosis via
massive dysregulation of pro- and antifibrogenic genes. J Hepatol 2005;43:1045-54.
44. Arvola A, Forsander O. Comparison between water and alcohol consumption in six animal species in free choice experiments. Nature
1961;191:819-20.
45. Holmes RS, Dudley JA, Algar EM, Mather PB, Rout UK. Biochemical and genetic studies on enzymes of alcohol metabolism: the mouse
as a model organism for human studies. Alcohol Alcohol 1986;21:41-56.
46. Bertola A. Rodent models of fatty liver diseases. Liver Res 2018;2:3-13.
47. Friemel J, Frick L, Unger K, Egger M, Parrotta R, et al. Characterization of HCC mouse models towards an etiology-oriented subtyping
approach. Mol Cancer Res 2019;17:1493-502.
48. Ambade A, Satishchandran A, Gyongyosi B, Lowe P, Szabo G. Adult mouse model of early hepatocellular carcinoma promoted by
alcoholic liver disease. World J Gastroenterol 2016;22:4091-108.
49. Rafacho BPM, Stice CP, Liu C, Greenberg AS, Ausman LM, et al. Inhibition of diethylnitrosamine-initiated alcohol-promoted hepatic
inflammation and precancerous lesions by flavonoid luteolin is associated with increased sirtuin 1 activity in mice. Hepatobiliary Surg
Nutr 2015;4:124-34.
50. Brandon-Warner E, Walling TL, Schrum LW, McKillop IH. Chronic ethanol feeding accelerates hepatocellular carcinoma progression in
a sex-dependent manner in a mouse model of hepatocarcinogenesis. Alcohol Clin Exp Res 2012;36:641-53.
51. Naugler WE, Sakurai T, Kim S, Maeda S, Kim K, et al. Gender disparity in liver cancer due to sex differences in MyD88-dependent IL-6
production. Science 2007;317:121-4.
52. De Minicis S, Kisseleva T, Francis H, Baroni GS, Benedetti A, et al. Liver carcinogenesis: rodent models of hepatocarcinoma and
cholangiocarcinoma. Dig Liver Dis 2013;45:450-9.
53. Xin B, Cui Y, Wang Y, Wang L, Yin J, et al. Combined use of alcohol in conventional chemical-induced mouse liver cancer model
improves the simulation of clinical characteristics of human hepatocellular carcinoma. Oncol Lett 2017;14:4722-8.
54. Liu K, McCaughan GW. Epidemiology and etiologic associations of non-alcoholic fatty liver disease and associated HCC. Adv Exp Med
Biol 2018;1061:3-18.
55. Wolf MJ, Adili A, Piotrowitz K, Abdullah Z, Boege Y, et al. Metabolic activation of intrahepatic CD8+ T cells and NKT cells causes
nonalcoholic steatohepatitis and liver cancer via cross-talk with hepatocytes. Cancer Cell 2014;26:549-64.
56. De Minicis S, Agostinelli L, Rychlicki C, Sorice GP, Saccomanno S, et al. HCC development is associated to peripheral insulin resistance
in a mouse model of NASH. PLoS One 2014;9:e97136.
57. Hill-Baskin AE, Markiewski MM, Buchner DA, Shao H, DeSantis D, et al. Diet-induced hepatocellular carcinoma in genetically
predisposed mice. Hum Mol Genet 2009;18:2975-88.
58. Kanuri G, Bergheim I. In vitro and in vivo models of non-alcoholic fatty liver disease (NAFLD). Int J Mol Sci 2013;14:11963-80.
59. Asgharpour A, Cazanave SC, Pacana T, Seneshaw M, Vincent R, et al. A diet-induced animal model of non-alcoholic fatty liver disease
and hepatocellular cancer. J Hepatol 2016;65:579-88.
60. Tsuchida T, Lee YA, Fujiwara N, Ybanez M, Allen B, et al. A simple diet- and chemical-induced murine NASH model with rapid
progression of steatohepatitis, fibrosis and liver cancer. J Hepatol 2018;69:385-95.
61. Kishida N, Matsuda S, Itano O, Shinoda M, Kitago M, et al. Development of a novel mouse model of hepatocellular carcinoma with
nonalcoholic steatohepatitis using a high-fat, choline-deficient diet and intraperitoneal injection of diethylnitrosamine. BMC Gastroenterol
2016;16:61.
62. Park EJ, Lee JH, Yu GY, He G, Ali SR, et al. Dietary and genetic obesity promote liver inflammation and tumorigenesis by enhancing
IL-6 and TNF expression. Cell 2010;140:197-208.
63. Liang JQ, Teoh N, Xu L, Pok S, Li X, et al. Dietary cholesterol promotes steatohepatitis related hepatocellular carcinoma through
dysregulated metabolism and calcium signaling. Nat Commun 2018;9:4490.
64. Henderson JM, Polak N, Chen J, Roediger B, Weninger W, et al. Multiple liver insults synergize to accelerate experimental hepatocellular
carcinoma. Sci Rep 2018;8:10283.
65. Castro RE, Diehl AM. Towards a definite mouse model of NAFLD. J Hepatol 2018;69:272-4.
66. Fujii M, Shibazaki Y, Wakamatsu K, Honda Y, Kawauchi Y, et al. A murine model for non-alcoholic steatohepatitis showing evidence of
association between diabetes and hepatocellular carcinoma. Med Mol Morphol 2013;46:141-52.
67. Febbraio MA, Reibe S, Shalapour S, Ooi GJ, Watt MJ, et al. Preclinical models for studying NASH-driven HCC: how useful are they?
Cell Metab 2019;29:18-26.
68. Takakura K, Koido S, Fujii M, Hashiguchi T, Shibazaki Y, et al. Characterization of non-alcoholic steatohepatitis-derived hepatocellular
carcinoma as a human stratification model in mice. Anticancer Res 2014;34:4849-55.
69. Arfianti E, Larter CZ, Lee S, Barn V, Haigh G, et al. Obesity and diabetes accelerate hepatocarcinogenesis via hepatocyte proliferation
independent of NF-κB or Akt/mTORC1. J Clin Transl Res 2016;2:26-37.
70. Teufel A, Itzel T, Erhart W, Brosch M, Wang XY, et al. Comparison of gene expression patterns between mouse models of nonalcoholic
fatty liver disease and liver tissues from patients. Gastroenterology 2016;151:513-25.